4.4 Article

Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling

Journal

BIOCHEMISTRY
Volume 47, Issue 6, Pages 1599-1607

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/bi7017927

Keywords

-

Funding

  1. Intramural NIH HHS Funding Source: Medline

Ask authors/readers for more resources

Molecular modeling and site directed mutagenesis were used to analyze the structural features determining the unique inhibitor sensitivities of type-III phosphatidylinositol 4-kinase enzymes (PI4Ks). Mutation of a highly conserved Tyr residue that provides the bottom of the hydrophobic pocket for ATP yielded a PI4KIII beta enzyme that showed greatly reduced wortmannin sensitivity and was catalytically still active. Similar substitutions were not tolerated in the type-III(x enzyme rendering it catalytically inactive. Two conserved Cys residues located in the active site of PI4KIII alpha were found responsible for the high sensitivity of this enzyme to the oxidizing agent, phenylarsine oxide. Mutation of one of these Cys residues reduced the phenylarsine oxide sensitivity of the enzyme to the same level observed with the PI4KIII beta protein. In search of inhibitors that would discriminate between the closely related PI4KIII alpha and -III beta enzymes, the PI3K gamma inhibitor, PIK93, was found to inhibit PI4KIII beta with significantly greater potency than PI4KIII alpha. These studies should aid development of subtype-specific inhibitors of type-III PI4Ks and help to better understand the significance of localized PtdIns4P production by the various PI4Ks isoforms in specific cellular compartments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available